KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Globus Medical (GMED) Total Liabilities (2016 - 2025)

Globus Medical's Total Liabilities history spans 15 years, with the latest figure at $729.5 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 32.1% year-over-year to $729.5 million; the TTM value through Dec 2025 reached $729.5 million, down 32.1%, while the annual FY2025 figure was $729.5 million, 32.1% down from the prior year.
  • Total Liabilities reached $729.5 million in Q4 2025 per GMED's latest filing, up from $696.8 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $1.2 billion in Q3 2023 to a low of $174.9 million in Q1 2021.
  • Average Total Liabilities over 5 years is $560.4 million, with a median of $428.9 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: soared 450.18% in 2023, then tumbled 38.99% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $215.9 million in 2021, then grew by 6.43% to $229.8 million in 2022, then skyrocketed by 373.61% to $1.1 billion in 2023, then dropped by 1.26% to $1.1 billion in 2024, then plummeted by 32.1% to $729.5 million in 2025.
  • Per Business Quant, the three most recent readings for GMED's Total Liabilities are $729.5 million (Q4 2025), $696.8 million (Q3 2025), and $665.4 million (Q2 2025).